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Abstract 32 
Purpose. Early prosthetic joint infection (PJI) can be treated with an intensive surgical debridement and 33 
implant retention (DAIR) of the prosthesis if 1) the prosthesis is stable, 2) the pathogen is not a difficult to 34 
treat microorganism, 3) symptoms have lasted for less than 3 weeks, and 4) a sinus tract is absent.  35 
Methods. We retrospectively evaluated the treatment outcome of early PJI in hip and knee in a single 36 
orthopaedic centre. An early PJI was defined as a prosthesis infection within 3 months after primary 37 
implantation or revision surgery for a non-infectious cause.  38 
Results. We found 69 cases with confirmed early PJI with a median age of 71 (range 33-84) years. Only 39 
64% presented with ≥ 2 acute signs of infection. The most commonly isolated bacteria were coagulase-40 
negative staphylococci (38%) and Staphylococcus aureus (25%). Surgical procedures included DAIR in 50 41 
(69%) and two-stage exchange in 19 (31%). At last follow up, five of 63 patients (7.9%) had a relapse of 42 
infection. The overall relapse free survival of prosthesis was 92.3% (95%, CI 82-97%) with no significant 43 
difference between DAIR and exchange of prosthesis.  44 
Conclusion. Our data suggest treating an early PJI with DAIR as a less invasive procedure whenever 45 
possible according to the established treatment algorithm.   46 
 2 
Introduction 47 
A periprosthetic joint infection (PJI) is a medical problem that is rising in importance worldwide because of 48 
increased usage of artificial joints [1]. PJI can be caused by direct inoculation of bacteria to the implant or 49 
by haematogenous seeding [2]. In the former case, bacteria from the commensal skin flora around the 50 
surgical site or from contamination by the health-care provider are introduced to the implant during or soon 51 
after surgery. The widest accepted classification of PJI proposed by a group from the Mayo clinic 52 
distinguishs between a stage one (or early) in which the infection occurs in the first 3 months after surgery, 53 
a stage two (or delayed) in which the infection occurs between 3 and 24 months after surgery and presents 54 
typically more indolent with a pain-free interval, and a stage three (or late) which includes infections that 55 
occur after 2 years and that are frequently caused by haematogenous dissemination of microbial pathogens 56 
[3, 4]. Based on this classification, in 2004 Zimmerli et al. have proposed an individual treatment algorithm 57 
for each stage to attain a high success rate with the least invasive surgical procedure [2]. Briefly, a delayed 58 
infection always needs an exchange of the prosthesis, whereas early (onset less than 3 months 59 
postoperative) or haematogenous infection can be cured by debridement and retention of the prosthesis 60 
provided that (i) the prosthesis is stable, (ii) the duration of symptoms does not exceed three weeks, (iii) 61 
there is intact skin and soft tissue, and (iv) the causative pathogen is susceptible to a biofilm active 62 
antibiotic [2].  63 
Recently, there has been intensive discussion about the optimum period of time after surgery that defines an 64 
early infection. Definitions range between two weeks and three months [2, 3, 5-7].  Furthermore, there is a 65 
wide range in definition of time (between 8 and 30 days) concerning the maximum duration of clinical 66 
signs and symptoms after which a debridement and retention (DAIR) approach may still lead to a 67 
successful outcome [8, 9]. In the recently published IDSA guidelines by Osmon et al. a DAIR strategy is 68 
recommended (evidence grade 2A) if infectious symptoms occur early within 30 days postoperatively or if 69 
length of symptoms is less than 3 weeks [7]. Herein, we retrospectively analysed the characteristics and 70 
outcome of early PJI in a 5-year cohort of hip and knee arthroplasties in a single centre. Since our centre 71 
defined an early PJI within 3 months postoperatively [2], we had the opportunity to investigate if there was 72 
any difference in outcome after DAIR if the definition of an early PJI was shortened from 3 months to one 73 
month. We speculated that patients with an early PJI not only present with typical acute inflammatory signs 74 
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and symptoms. Furthermore we attempted whether there was a difference in the clinical outcome of PJI if 75 
signs and symptoms last longer than 3 weeks until a surgical procedure was performed.  76 
Materials and Methods 77 
Study design and population. 78 
The Schulthess Clinic Zurich is a specialized 160-bed orthopaedic centre with a high rate of surgical 79 
interventions (7491 inpatient and 1221 outpatient treatments documented in 2012; 804 primary hip and 579 80 
knee arthroplasties). We retrospectively reviewed all early postoperative exogenous types of infection after 81 
a knee or hip prosthesis implantation (either after primary arthroplasty or revision surgery) presenting in the 82 
Schulthess Clinic between January 2005 and June 2010. Clinical information on infection was retrieved 83 
from the prospectively managed database on all PJI from the Infectious Diseases Clinical Consulting 84 
Service and from the hospital information system managed by the Schulthess Clinic in Zurich. Patients 85 
with a delayed infection (onset of symptoms 3 to 24 months after the last surgery) as well as patients with 86 
an incomplete follow-up were excluded.  87 
Definitions 88 
Prosthetic joint infection (PJI) was diagnosed, if one or more of the following criteria were fulfilled: (i) 89 
visible purulence of a preoperative aspirate or intraoperative periprosthetic tissue (as determined by the 90 
surgeon), (ii) presence of a sinus tract communicating with the prosthesis, (iii) microbial growth in a 91 
preoperative joint aspirate, intraoperative periprosthetic tissue or sonication fluid of the removed implant 92 
[2, 7]. As a very early prosthetic joint infection we defined a prosthesis infection with symptom onset ≤ 1 93 
month after primary or revision surgery of knee or hip prosthesis [2] and an early manifestation ≥ 1 and ≤ 3 94 
months. In case of a non-healing wound discharge postoperatively we defined the onset of symptoms 14 95 
days after the surgical operation. If an infection was diagnosed with a revision surgery due to wound 96 
discharge or postoperative hematoma within 14 days, the date of the revision operation was defined as the 97 
onset of symptoms.  98 
PJI symptoms were divided in ≥ or <2 typical acute inflammatory signs (such as pain, purulent wound 99 
discharge, erythema, swelling/induration or warmth of the joint, optionally fever), chronic symptoms such 100 
 4 
as sinus tract, or other non-specific signs such as, hematoma, joint effusion or luxation, or elevated 101 
inflammatory serum biomarker only. 102 
Surgical and antibiotic treatment of early infection 103 
The surgical approach was individually determined at the surgeon’s discretion in discussion with the 104 
Infectious Disease Consulting Service. There were mainly three potential approaches: (i) debridement 105 
antibiotics and implant retention (DAIR), (ii) one- or two-stage exchange of the implant, or (iii) resection 106 
arthroplasty. If only parts of the prosthesis were removed, we considered the surgical procedure as a DAIR. 107 
For the best outcome with a DAIR, orthopaedic surgeons always went for an arthrotomy instead for an 108 
arthoscopy for a better infection control and for cultivating bacteria originating from biofilm and not 109 
planktonic bacteria. During the study period, exchange of all mobile parts, type of lavage, and second look 110 
surgeries was individually determined at the surgeon’s discretion. 111 
The duration of antibiotic treatment was planned either for 3 months in case of patients with hip prosthesis, 112 
or for 6 months for patients with knee arthroplasty as recommended in guidelines [7]. An initial intravenous 113 
therapy of at least 14 days was planned [2, 7].   114 
Outcome evaluation 115 
Follow-up visits were performed at the outpatient Department of Schulthess Clinic. The patients were 116 
followed up for relapse of infection, new infection or death. We defined a relapse of infection if: (i) signs 117 
and symptoms of a persistent infection (i.e. communicating sinus tract with the prosthesis) were present 118 
after 21 days of an adequate surgical and antibiotic treatment, and/or (ii) the same pathogen either as a 119 
monobacterial or polymicrobial infection was re-isolated within 2 years after infection diagnosis, and/or 120 
(iii) if death was directly related to the PJI diagnosis [10-13]. Patients who died early due to the sequela of 121 
a sepsis (e.g pneumonia) or late to any illness were not defined as relapses. A revision operation within 21 122 
days after the first therapeutic surgical procedure was not considered as a relapse. The most invasive 123 
surgical approach was reported as the definitive surgical treatment. A new infection was defined as a PJI at 124 
the same anatomical site with isolation of a different microbial pathogen. Cases of death were allocated to 125 
infection or non-infection related. Successful response was postulated if the patient had no signs and 126 
symptoms of relapse and was not receiving suppressive antibiotic treatment after a follow up period of at 127 
least 24 months.  128 
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Statistical analysis 129 
GraphPad Prism 6 software (GraphPad, San Diego, CA) was used for statistical calculations and 130 
performing figures. The probability of relapse-free survival and the 95% confidence interval (95% CI) was 131 
estimated using the Kaplan Meier survival method.  Cox proportional hazard analysis was used for 132 
comparison of relapse free survivals of different surgical subgroups. Observations were censored at the 133 
time of diagnosis of infection relapse. Categorical variables were compared by the chi-square test or 134 
Fisher’s exact test.  135 
Results 136 
Baseline characteristics 137 
Between January 2005 and June 2010, 864 patients with a possible PJI of the knee (n = 456) or hips (n = 138 
408) treated at the Schulthess Clinic in Zurich were documented in the databank of the Infectious Disease 139 
Service. Seventy-five (8.7%) patients of these presented in the early postoperative period within 3 months 140 
after surgery. Six patients were excluded because of an incomplete follow-up, so that 69 early infections 141 
were further analysed (28 knee, 41 hip prostheses). Characteristics of all 69 patients are summarized in 142 
table 1. The left side of the hip or knee joint was more affected by an early infection (60.9% vs. 39.1%).  143 
Symptoms 144 
The median time between the last surgical procedure and onset of symptoms of infection was 14 days and 145 
until diagnostic and therapeutic surgical intervention for infection 22 days (table 2). In 58 of 69 cases 146 
(84%) first symptoms of infection manifested within 30 days, in 11 cases (16%) between 30 and 90 days. 147 
In 60 of 69 patients (87%), symptoms lasted less than 3 weeks until a diagnostic and therapeutic surgical 148 
revision for infection was performed.  149 
Forty-four patients (64%) showed ≥2 typical acute inflammatory symptoms such as pain, 150 
erythema, wound discharge, swelling/induration, or local warmth of the joint (table 2 and 3). Fifteen of 151 
these patients also developed fever, 10 of them with positive blood cultures, two died due to sepsis. Only 152 
one inflammatory sign of infection was documented in twelve (17%), signs of a chronic infection such as 153 
sinus tract in five patients. In eight patients, non-inflammatory signs and symptoms such as haematoma, 154 
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joint effusion or luxation, or elevated inflammatory serum biomarker only were the leading symptoms of 155 
the infection.  156 
Diagnostic procedure 157 
In the majority (67 of 69) of patients, microbial growth was detected preoperatively and/or intraoperatively. 158 
The two patients with culture negative PJI showed highly infection-suspicious intraoperative signs 159 
according to the orthopaedic surgeon, but were treated with antibiotics for 3 days and 20 days, respectively. 160 
The mean number of intraoperatively retrieved tissue biopsies was 5.6 (range 2-11) in order to facilitate the 161 
differentiation between causing pathogen and contaminants. Most commonly isolated microorganisms were 162 
S. aureus (17, 38%) and coagulase-negative staphylococci (26, 25%)  with methicillin resistance in 1 of 17 163 
(6%) and 24 of 26 (92%), respectively (table 3). Many virulent microorganisms, such as Staphylococcus 164 
aureus, Streptococcus pyogenes, S. agalactiae, S. dysgalactiae subsp. equisimilis, or Bacillus cereus, 165 
presented with acute clinical manifestation, whereas many patients with low-virulent pathogens such as 166 
coagulase-negative staphylococci, Enterococcus faecalis, or Propionibacterium acnes presented with 167 
delayed (sinus tract) or nonspecific symptoms (table 3).  168 
Antibiotic treatment 169 
The median time of antibiotic treatment was 3.1 months for hip and 6.1 months for knee PJI (table 2), 170 
calculated for all patients including the 2 cases with early death due to sepsis at day 9 and 27. Initial 171 
intravenous therapy was performed for at least 14 days in 56 of 69 cases (81%). Antimicrobial treatment 172 
was chosen according to susceptibility testing of the pathogen with an initial empirical treatment consisting 173 
of an intravenous broad-spectrum beta-lactam antibiotic in combination with rifampin. In two patients with 174 
a culture-negative PJI, intravenous empirical treatment was followed by an oral treatment with a 175 
fluoroquinolone (ciprofloxacin or levofloxacin) and rifampin. In patients with a Staphylococcus species or 176 
Propionibacterium acnes PJI, a rifampin-combination regime was given as a potent antimicrobial substance 177 
against bacteria in biofilm [14, 15]. The infectious diseases consultant chose the combination antimicrobial 178 
drug according to antimicrobial susceptibility testing (preferably a fluoroquinolone) to avoid emergence of 179 
rifampin resistance [16].  180 
 181 
Surgical treatment 182 
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In the majority of patients (n=50, 72.5%), DAIR of the prosthesis as the most invasive procedure was 183 
performed. In 15 of these 50 patients (30%), a second-look operation with a repeated DAIR was done 184 
within 2 to 18 days (median 6 days) due to hematoma (n=1), wound discharge (n=10), or routinely (n=4). 185 
In all but one (S. aureus, intervention at day 6), intraoperative tissue biopsies at second look were negative.  186 
These cases with repeated DAIR were not interpreted as treatment failure because of intervention within 21 187 
days after the initial surgical process.  188 
In 19 patients (27.5%), a complete two-stage exchange of the prosthesis was chosen, thereof in seven 189 
patients after an initial DAIR within 20 days (median 14, range 6 to 20 days). Reason for an exchange were 190 
(i) symptoms lasting for longer than 3 weeks (n=4), (ii) diagnosis of a rifampin-resistant staphylococcus 191 
(n=1), (iii) hepatopathy with intolerance to rifampin in case of a staphylococcal PJI (n=1), or (vi) severely 192 
damaged periprosthetic tissue (n=13). No resection arthroplasty or one-stage exchange of the prosthesis 193 
was performed. In case of a two-stage prosthetic exchange, the median time between removal and 194 
replacement was 3.4 months (range 0.5 to 14.9 months).  195 
 196 
Outcome analysis 197 
Two patients died due to sequelae of sepsis caused by S. epidermidis at day 9 and day 27 postoperatively. 198 
At last follow-up 62 of 67 remaining patients were free of infection (median 3.1 years, range 0.2-6.5 years) 199 
and five had a relapse of infection (median time to relapse 0.6 years, range 0.2 -0.9 years) with isolation of 200 
the same microorganism (n = 3) or a persistent wound discharge or sinus tract > 3 weeks under continuous 201 
antibiotic treatment (n = 2). Causing pathogens were methicillin-resistant Staphylococcus epidermidis (n = 202 
3), methicillin-susceptible S. aureus (n = 1) and one mixed infection with isolation of Proteus mirabilis and 203 
Enterococcus faecalis. Two patients died 4 and 11 months after surgery due to a non-infectious reason. In 204 
seven cases (11.1%), a new infection with another microorganism was documented.  205 
The relapse-free survival of the prosthesis in 67 patients (69 minus 2 deaths due to sequela of sepsis) was 206 
92.3% (95% CI 82.6-97%) after 2 years (figure 1A). Stratified by surgical procedure, the relapse-free 207 
survival of the prosthesis was 91.6% (95% CI 79.2-96.8) for debridement with retention of the prosthesis 208 
and 94.2% (95% CI 65-99.2%) for exchange of the prosthesis (figure 1B) after 2 years.  209 
 210 
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Outcome stratified according to time of manifestation of infection 212 
In 58 of 69 patients (84%) signs of symptoms of infection developed within 30 days after surgery (very 213 
early) and in 11 patients (16%) between 30 and 90 days (early). All five relapses occurred in the group with 214 
very early manifestation of clinical symptoms (four relapses after DAIR, one relapse after a two-stage 215 
exchange of prosthesis)..Among the patients treated with debridement and retention of the prosthesis, no 216 
significant difference in cure rate was calculated for patients with onset of symptoms less or more than 30 217 
days after last surgery (Fischer’s exact test, p=1). 218 
Outcome stratified according to duration of symptoms 219 
In recent expert recommendations and guidelines (evidence grade 2A), it is recommended to treat a PJI 220 
with a DAIR if signs and symptoms have lasted less than 3 weeks [2, 7, 17]. From our 69 patients, nine 221 
patients (13%) showed clinical symptoms for more than 3 weeks until a diagnostic and therapeutic 222 
intervention was performed. Four of these nine patients (44%) were finally treated with a two-stage 223 
exchange, five with DAIR of the prosthesis and two (one treated with DAIR and one with two-stage 224 
exchange) developed a relapse of infection. The possible reason for these relapses might have been  a 225 
persistent biofilm infection due to a remaining screw after complete exchange of the prosthesis and a 226 
remaining bone sequester after DAIR.  227 
Among all 60 patients with symptoms less than 3 weeks finally treated with DAIR in 45 and two-stage 228 
exchange in five, three patients developed a relapse of infection after DAIR. There was no significant 229 
difference in cure rates according to duration of symptoms less or more than 3 weeks (Fisher’s exact test, 230 
p=0.4).  231 
Discussion 232 
Our retrospective analysis of 69 early infections after implantation of a knee or hip prosthesis shows that 233 
only 64% of the patients present with ≥2 acute inflammatory symptoms. Staphylococcus aureus (25%), 234 
coagulase-negative staphylococci (38%), and Gram-negative bacteria (11.6%), were the most commonly 235 
found causative organisms in early PJI. Thus, low virulent pathogens such as coagulase-negative 236 
staphylococci quite commonly cause early infection.  237 
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Two thirds of the patients with early PJI showed ≥ 2 acute symptoms of an infection such as pain, 238 
wound discharge, erythema, swelling/induration or warmth of the joint and/or fever. About one third 239 
presented with only one acute inflammatory symptom, or signs of a chronic infection (sinus tract, 240 
hematoma, joint effusion/luxation, or elevated inflammatory serum biomarkers only). Typically, early 241 
infections are considered to be associated with acute infectious symptoms [2], but still, many patients 242 
exclusively suffer from nonspecific symptoms [18]. From our results, we conclude that even in early PJI 243 
non-specific symptoms should raise the suspicion of a potential deep prosthetic joint infection and further 244 
diagnostic steps such as arthrocentesis and synovial fluid analysis (total and white cell count, 245 
microbiological culture) should be enforced. In our study, the most commonly isolated microorganisms 246 
were coagulase-negative staphylococci. Thus, these low-virulence microorganisms are not limited to 247 
delayed infection.  248 
The goal of treatment in PJI is to cure the infection, prevent its recurrence, and ensure a pain-free 249 
and functional joint [19]. Despite the recently published IDSA guidelines on PJI [7], the proposed 250 
therapeutic approach is still under debate, since many recommendations are based on non-randomized 251 
observational studies and/or expert opinion. There is only one randomized double blinded prospective trial 252 
with 33 patients demonstrating that in early staphylococcal PJI, DAIR is a successful treatment provided 253 
that a combination of rifampin with a fluoroquinolone (ciprofloxacin) is used [14]. Large cohort studies or 254 
randomized controlled trials with high power are still missing. In the US, PJI is traditionally treated with a 255 
two-stage exchange, whereas in Europe the approach of extensive debridement, antibiotics, and implant 256 
retention (DAIR) is more regularly used. DAIR is favoured if the prosthesis is stable, the pathogen is not a 257 
difficult-to-treat microorganism, symptoms have lasted for less than 3 weeks, and skin and soft tissue are 258 
intact [2]. For a successful debridement mobile parts of the prosthesis (polyethylene inlay) should be 259 
replaced [20, 21], because the lack of removal was shown to be an independent risk factor for treatment 260 
failure in an investigation of Choi et al [21]. In general, debridement and retention of the prosthesis is 261 
favoured because of a lower morbidity due to a less invasive surgery and reduction of cost due to a shorter 262 
hospital stay [22]. Our study showed a successful outcome with a prosthesis survival rate of 92%, without a 263 
significant difference between retention and exchange of the prosthesis. These findings support the result of 264 
previous published studies in particular the prospective randomized study by Zimmerli et.al studying the 265 
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outcome of early staphylococcal infections [14, 23-25]. This study showed a 100% treatment success with 266 
DAIR if rifampin was combined with ciprofloxacin and no radiological sign of loosening was detected [2]. 267 
Without use of rifampin, treatment success was 58% only. Our study confirmed the good outcome of DAIR 268 
treatment with extension to other microbial pathogens than staphylococci. But if patients are not properly 269 
selected or if a polymicrobial infection was diagnosed, poorer outcome with debridement and retention was 270 
found [11, 12, 26].  271 
In the literature, duration of symptoms was stressed to be an important risk factor for successful 272 
debridement and retention [2, 8]. Taking into account the low number of relapses in our study, we could not 273 
find any difference between patients treated with DAIR with duration of symptoms of less or more than 3 274 
weeks. The reason for treatment failure in 4 patients with DAIR was (i) suppressive treatment without 275 
rifampin from the beginning because of non-adherence (iv-drug use) and liver cirrhosis, (ii) intolerance to 276 
rifampin, (iii) polymicrobial infection, and (iv) a remaining bone sequester after debridement.  In the one 277 
patient with treatment failure after two-stage exchange, a screw for a fixation device remained in situ and 278 
could not be removed, which caused persistent infection.  279 
Patients in our study received a long-term antibiotic treatment with a median duration of 3.1 in hip 280 
or 6.1 months in knee PJI, which is based on European and American guidelines [7, 27]. A total treatment 281 
period of 3 months for hip and 6 months for knee joint infections was recommended earlier [2]. A cohort 282 
study from Australia with 147 patients with early PJI recently found that a shortened treatment course for 283 
less than 3 months is a risk factor for treatment failure [6]. However, recently published studies favour 284 
shorter treatments [28-31], but no randomized controlled trials exist up to now.  285 
No consensus exists on the period of time after surgery that defines an early infection. Definitions 286 
range between two weeks and three months [2, 3, 5-7]. In our study, no difference in outcome was seen in 287 
patients presenting with very early (≤ 30 days) and early (30-90 days) manifestation of PJI. This underlines 288 
the probably more important fact of consequent use of rifampin in staphylococcal infections and choosing 289 
DAIR as treatment option only after proper selection of patients with a stable prosthesis.  290 
This study provides important epidemiological and clinical data about early PJI and its treatment 291 
possibilities. It especially underlines the good outcome with DAIR in a properly selected cohort of patients 292 
and supports the data of a previously randomized controlled study of Zimmerli et al. with extension to a 293 
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variety of microbial pathogens. Limitations of the study are the retrospective design and the low number of 294 
patients with symptoms longer than 3 weeks or early symptom onset between 30 and 90 days, which did 295 
not allow us to perform a risk factor analysis. The studied cohort population was heterogeneous with 296 
respect to different isolated pathogens, and because we did not distinguish between primary and revision 297 
surgery procedures. This might have led to mistaking a low-grade infection for an early infection after 298 
revision surgery in some cases.  299 
In conclusion, our investigation shows that DAIR is not inferior to two-stage exchange of the 300 
prosthesis. Therefore, whenever possible according to an established treatment algorithm, early PJI should 301 
be treated with DAIR, since it is less invasive. A high cure rate of >90% can be reached with DAIR 302 
provided that patients are properly selected, and an experienced multidisciplinary team of orthopaedic 303 
surgeons, infectious disease specialists and microbiologists evaluates each case. 304 
 305 
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Tables and Figures 310 
Table 1. Baseline characteristics of 69 patients with an early periprosthetic joint knee- (n=28) and hip 311 
infection (n=41) 312 
Characteristics No. of episodes (%) 
Median age (years) 71 (33 – 84) 
Females 34 (49.3) 
Primary implantation of the prosthesis 
 Schulthess Clinic 
 External hospital 
 
55 (79.7) 
14 (20.3) 
Last surgical procedure before infection 
 Primary implantation 
 Revision surgery 
o 1 
o ≥ 2 
 
37 (53.6%) 
32 (46.4%) 
19 
13 
Localization of joint prosthesis 
 Knee 
 Hip 
 Left side of implantation 
 
28 (40.6%) 
41 (59.4%) 
42 (60.9) 
Underlying joint disorder 
 Degenerative 
 Posttraumatic 
 Rheumatoid arthritis 
 Osteosarcoma 
 
58 (84) 
6 (8.7) 
4 (5.8) 
1 (1.4) 
 Comorbidity 
 Diabetes mellitus 
 Obesity 
 Neoplasia 
 Immunosuppression 
 
10 (14.5) 
20 (29.0) 
5 (7.2) 
12 (17.4) 
 13 
Table 2. Characteristics of 69 early PJI (knee- n=28, hip n=41)  
Characteristics N (%)  
Pathogenesis 
 Perioperatively acquired (exogenous) 
 Hematogenous 
 
62 (89.9%) 
7 (11.1%) 
Time to manifestation of symptoms (days), median (range) 
 Last surgical intervention to onset of symptoms 
  Very early presentation (≤ 1 month) 
  Early presentation (> 1 month - ≤ 3 months) 
 Last surgical intervention to infection diagnosis 
  Length of symptoms ≤ 3 weeks 
  Length of symptoms > 3 weeks 
 Duration of symptoms until surgical management of infection 
 
14 (2 - 68) 
 58 (84%) 
 11 (16%) 
22 (2 – 92) 
 60 (87%)
 9 (13%) 
5 (0 – 78) 
Symptoms 
 ≥2 inflammatory signs and symptomsa 
  + fever 
 <2 inflammatory signs and symptoms 
  Wound dehiscence or discharge only 
  Persistent pain only 
  Warmth only 
 Sinus tract 
 Other signs and symptoms 
  Hematoma 
  Joint effusion 
  Joint luxation 
  Elevated inflammatory biomarker only 
 
44 (64%) 
 15 
12 (17%) 
 8 
 3 
 1 
5 (7%) 
8 (12%) 
 3 
 2 
 2 
 1  
 14 
Antibiotic treatment, median months (range) 
 Intravenous (days) 
 Knee, median month (range) 
 Hip, median month (range) 
3.5 (0.3-8.3) 
17 (7-126) 
6.1 (1.3-8.3) 
3.1 (0.3-6.7) 
Surgical treatment 
 Debridement and retention (DAIR) 
  + exchange of polyethylene inlay 
  + exchange of a part of the prosthesis 
 Two-stage exchange of the prosthesis 
  As the initial surgical approach 
  Within 20 days after initial DAIR  
 
50 (72.5%) 
 17 
 9 
19 (27.5%) 
 12 
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a ≥ 2 manifestation of inflammation such as pain, purulent wound discharge, erythema, swelling/induration 313 
or warmth of the joint314 
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Table 3. Microbiological characteristics with description of signs and symptoms of 69 patients with early PJI 315 
Microbial pathogen N (%) 
 N (%) ≥2 inflammatory 
signs/symptomsd 
 
+ fever 
<2 inflammatory 
signs/symptoms 
Sinus tract Other 
signs/symptomse 
Monobacterial 
 Staphylococcus aureusa 
 Coagulase-negative staphylococcusb 
 Streptococcus pyogenes 
 Streptococcus dysgalactiae  
  subsp. equisimilis 
 Streptococcus agalactiae 
 Enterococcus faecalis 
 Bacillus cereus 
 Escherichia colic 
 Citrobacter koseric 
 Pseudomonas aeruginosac 
 Enterobacter cloacaec 
 Haemophilus parainfluenzac 
64 (92.7) 
 17  
 26 
 1 
 1 
 
 2 
 1 
 1 
 3 
 2 
 1 
 1 
 1 
44 (64) 
 16 
 13 
 1 
 1 
 
 2 
 0 
 1 
 2 
 1 
 0 
 1 
 0 
15 
6 
0 
0 
1 
 
1 
0 
1 
1 
0 
0 
1 
1 
12 (17) 
 1 
 7 
 0 
 0 
 
 0 
 0 
 0 
 1 
 1 
 0 
 0 
 0 
5 (7) 
 0 
 2 
 0 
 0 
 
 0 
 1 
 0 
 0 
 0 
 0 
 0 
 0 
8 (12) 
 0 
 4 
 0 
 0 
 
 0 
 0 
 0 
 0 
 0 
 1 
 0 
 1 
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 Proteus mirabilisc 
 Propionibacterium acnes 
 Granulicatella adjacens 
 Clostridium hastiformis 
 Candida famata 
 1 
 3 
 1 
 1 
 1 
 1 
 1 
 0 
 0 
 0 
0 
0 
1 
1 
0 
 0 
 1 
 1 
 0 
 0 
 0 
 0 
 0 
 1 
 1 
0 
1 
0 
0 
0 
Polymicrobiald 3 (4.4)  2 0  0  0  1 
Culture negative 2 (2.9)  2 1  0  0  0 
a Susceptibility testing: n=16 methicillin susceptible, n=1 methicillin resistant 316 
b Coagulase-negative staphylococci included S. epidermidis (n=22), S. haemolyticus (n=2), S. capitis (n=2); n=24 methicillin resistant, n=2 methicillin 317 
susceptible 318 
c No multidrug-resistant Gram-negative pathogens 319 
d Polymicrobial infections included: S. epidermidis, P. acnes (n=1); Proteus mirabilis, S. aureus, Enterococcus faecalis (n=1), S. epidermidis, E. faecalis 320 
(n=1) 321 
e ≥ 2 manifestation of inflammation such as pain, purulent wound discharge, erythema, swelling/induration or warmth of the joint 322 
e haematoma, joint effusion or luxation, elevated inflammatory serum biomarker only 323 
 324 
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Table 4. Relapse of early periprosthetic joint infection (PJI) (n=5) 325 
No. Age, 
sex 
Joint Infecting organism Time after last 
surgery 
(months) 
Durations of 
symptoms 
(days) 
Surgical 
treatment 
Antimicrobial treatment (total 
duration of treatment) 
Time to 
relapse 
(months) 
1 67, 
w 
Hip S. epidermidis, mr 0.5 
 
1 DAIR Amoxicillin-clavulanate iv, 
trimethoprim-sulfamethoxazole po 
(suppression). No iv treatment 
3.1 during 
suppression 
medication 
2 76, 
w 
Hip S. epidermidis, mr 0.8 1 DAIR, exchange 
of part of 
prosthesis 
Vancomycin iv/R po,  
fusidic acid po/R po (3.6 months) 
11.8 
3 64, 
m 
Knee Polymicrobial (P. 
mirabilis, E. 
faecalis, S. aureus, 
ms) 
0.4 1 DAIR Imipenem-cilastin iv/R po, amoxicillin-
clavulanate iv/R po, ciprofloxacin po/R 
po (6.1 months) 
6.7 
4 51, 
w 
Hip S. aureus, ms 0.3 44 DAIR. Bone 
sequester in situ 
Flucloxacillin iv/R po, levofloxacin 
po/R po (4.5 months) 
6.6 
 18 
5 76, 
w 
Hip S. epidermidis, mr 0. 12 Two-stage 
exchange, screw 
remained in situ 
Daptomycin iv/R po, linezolid po/R po, 
trimethoprim-sulfamethoxazole po 
(suppression) 
1.8 during 
suppression 
R, rifampicin; mr, methicillin resistant; iv, intravenous; po, peroral 326 
 327 
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Figure 1. Kaplan Meier curve with relapse free survival of prosthesis in 69 patients (A) and stratified, if 328 
treatment with a debridement and retention (n=49) or exchange of the prosthesis (n=20) was performed (B). 329 
In A, dotted lines represent 95% confidence interval (CI). The relapse-free survival of the prosthesis in 67 330 
patients (69 minus 2 deaths due to sepsis) was 92.3% (95% CI 82.6-97%) after 2 years (A). Stratified by 331 
surgical procedure, the relapse-free survival of the prosthesis was 91.6% (95% CI 79.2-96.8) for DAIR and 332 
94.2% (95% CI 65-99.2%) for exchange of the prosthesis (B) after 2 years. 333 
  334 
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